drugset / Trial / NCT05130060
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase Ib trial studies the safety and side effects of a vaccine (PolyPEPI1018 vaccine) in combination with TAS-102 in treating patients with colorectal that has spread to other parts of the body (metastatic). PolyPEPI1018 peptide vaccine is used to immunize against proteins present on the surface of tumor cells. This vaccine can activate the body's immune cells, called T cells. T cells fight infections and can also kill cancer cells. TAS-102 may help block the formation of growths that may become cancer. Giving PolyPEPI1018 and TAS-102 may kill more tumor cells in patients with metastatic colorectal cancer.
Timeline
- Start
- 2022-01-10
- Primary completion
- 2023-06-11
- Completion
- 2023-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PolyPEPI1018 | Vaccine | — | Subcutaneous |
| Background | Tipiracil | Small molecule | — | Oral |
| Background | Trifluridine | Small molecule | — | Oral |